Congenital cytomegalovirus (CMV) infection is a major cause of birth defects and childhood disorders in the United States. Retinitis occurs in 25% of infants with severely symptomatic congenital CMV and in B1% of asymptomatic infants. Intravitreal ganciclovir is recommended in adults with CMV retinitis (CMVR) refractory or noncompliant to intravenous therapy. No literature is available discussing the use of intravitreal ganciclovir for CMVR in neonates. We report a term neonate who received intravenous and intravitreal ganciclovir for treatment of CMVR. Three doses of intravitreal ganciclovir (2 mg per dose in each eye) were administered. Intravitreal injections of ganciclovir appeared to be well tolerated and improvement of the retinitis was appreciated. Intravitreal ganciclovir is an effective treatment of CMVR in adult acquired immunodeficiency syndrome (AIDS) patients. We report one case of intravitreal ganciclovir in a term neonate with promising results.
INTRODUCTION
Congenital cytomegalovirus (CMV) infection is a major cause of birth defects and childhood disorders in the United States. It is estimated that about 40 000 children (0.2-2% of all deliveries) are born with CMV, resulting in B400 fatalities each year. 1 Transplacental transmission of the virus occurs in about onethird of mothers with primary CMV infection. Approximately half of these infections in utero result in a symptomatic clinical syndrome. Retinitis may be associated in 25% of infants with severely symptomatic congenital CMV and in 1% of asymptomatic infants. 2 Adult patients with acquired immunodeficiency syndrome (AIDS) represent the population where the majority of literature is available regarding the therapy for CMV retinitis (CMVR) as up to 29% of these patients develop CMVR. 3 Ganciclovir readily distributes to most body fluids, tissues and organs, including the eye and central nervous system. Ganciclovir has an 88% response rate in adult patients with CMVR secondary to AIDS. 4 Relapses may occur because of natural progression of disease or lack of patient compliance. 4, 5, 6 In the AIDS population, intravitreal ganciclovir is primarily reserved for salvage therapy, noncompliance or if significant adverse effects occur with systemic therapy. 7, 8, 9 Intravenous ganciclovir is a standard of therapy for CMV along with other DNA polymerase inhibitors. Systemic therapy with ganciclovir is used in symptomatic infants to reduce hearing loss and improve CMVR. 10, 11, 12 In adults, intravitreal ganciclovir at wide ranges of dosing have been reported to be as efficacious as intravenous ganciclovir with the potential to have improved outcomes. 9, 13 Improvements in infants with CMVR with intravenous ganciclovir are limited to case reports.
14 No published literature exists regarding the use of intravitreal ganciclovir in neonates with CMVR.
CASE
A term male infant was born via cesarean section secondary to fetal intolerance and decelerations. The mother had limited prenatal care, no history of any infections and prenatal ultrasound showed oligohydramnios. After birth, the infant was placed on continuous positive airway pressure ventilation for respiratory distress. The infant had symmetrical intrauterine growth restriction (birth weight less than third percentile) and was microcephalic (head circumference less than third percentile). On examination, a hyphema was noted in the right eye and a red reflex was absent. The patient had an absent gag reflex and had generalized hypertonia. Infant was evaluated for intrauterine growth restriction, including toxoplasmosis, rubella, cytomegalovirus, herpes simplex and human immunodeficiency virus.
The urine CMV spin-test report was positive and serum immunoglobulin-M for cytomegalovirus was elevated at 2.17 (positive defined as 41.11). A repeat urine culture was positive for CMV. A brain magnetic resonance imaging on the day of admission showed enlargement of the ventricular system with findings of a prior ventricular hemorrhage, varying stages of evolution with probable ependymal calcifications and dandy walker continuum, which were most consistent with antenatal Toxoplasmosis, Rubella, Cytomegalovirus And Herpes (TORCH) infection. In addition, the patient had thrombocytopenia, diabetes insipidus and a failed auditory brain stem response test in both the ears.
The ophthalmology examination showed engorged iris vessels and a clear lens in both the eyes. The right eye was found to have a dense vitreous hemorrhage. B scan confirmed the hemorrhage and an absence of retinal detachment. The left eye showed a normal appearing optic nerve, dilated vessels with pronounced frosted branch angiitis and retinal hemorrhages (Figure 1) .
After consulting the infectious disease team, the patient was started on ganciclovir 6 mg kg À 1 per dose intravenously every 12 h. Quantitative urine CMV PCR was 3.4 million copies ml À 1 and the serum CMV PCR was 74 000 copies ml À 1 before the initiation of therapy. Intravenous ganciclovir was initiated on day of life 10 through day of life 23. Owing to extent of ocular disease, the decision was made on day of life 13 to treat both the eyes with intravitreal ganciclovir. Injections of 2 mg of ganciclovir in 0.04 ml of normal saline (50 mg ml À 1 ) were prepared under sterile conditions with the intent of injections twice per week. After 10 days, the decision was made by the family to no longer continue the therapy with intravitreal or intravenous ganciclovir. After receiving 13 days of IV gancyclovir and three doses of intravitreal gancyclovir in both the eyes, the urine CMV PCR was 1 000 000 copies ml À 1 . The right retina remained unable to be visualized because of hemorrhage but the left retina showed improvement (Figure 2 ). The intravitreal injections appeared to be well tolerated by the infant.
DISCUSSION
Systemic ganciclovir has been used for decades for symptomatic CMV in infants with limited literature to support its use. Although prompt treatment may be an important prognostic factor in congenital CMV, optimal therapy for CMVR in children has not been well defined. Intravitreal ganciclovir 200-2000 mg once weekly has been studied in several nonrandomized studies in the management of adult CMVR. [7] [8] [9] A retrospective study in 42 adult AIDS patients assessed the use of high-dose intravitreal ganciclovir given twice a week for 3 weeks, followed by maintenance therapy once a week. Patients who had received long-term intravenous ganciclovir therapy previously were used as control. Ganciclovir 20 mg ml À 1 was prepared and dosed at 2 mg per 0.1 ml for each intravitreal injection. Seventy-four eyes were treated for a median duration of 34 weeks. Relapse occurred in 5/42 eyes with intravitreal ganciclovir compared with 15/18 eyes with intravenous ganciclovir. Patients receiving intravitreal ganciclovir were able to maintain their initial visual acuity between 20/20 to 20/40 (85%) compared with intravenous ganciclovir (59%). Three cases (0.2% of injections) of endophthalmitis and three cases of retinal detachment were seen. The cases of retinal detachment were considered high risk for detachment, and the authors did not feel detachment was temporally related to the injection. 9 Intravitreal therapy may be preferable to intravenous therapy as higher concentrations are attainable in the vitreous while minimizing systemic exposure. Following a 5 mg kg À 1 dose of intravenous ganciclovir, mean peak and trough levels in serum have been reported as 8-11 and 0.6-1.2 mcg ml . Intravitreal concentrations 72 hours after a 2-mg dose of intravitreal ganciclovir were 23.4 mcg ml À 1 in a small adult study. Vitreous levels decline with a half life of B18 h. 17 Our patient received both systemic and intraocular treatment ganciclovir, however, the treatment was incomplete as care was withdrawn.
CONCLUSION
Intravitreal ganciclovir is an effective agent for the treatment of CMVR in adult AIDS patients. We report one case of intravitreal ganciclovir in a term neonate with promising results. Three intravitreal injections of 2 mg in each eye were well tolerated and resulted in significant improvement in retinitis. While larger studies are needed, our case indicates that intravitreal ganciclovir may be an option in term neonates with CMVR.
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